Compare, Analyse Divis Laboratories with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   ADCOCK INGRAM
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ADCOCK INGRAM
Jun-14
DIVIS LABORATORIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,639347-   
Low Rs1,115251-   
Sales per share (Unadj.) Rs186.3103.3-  
Earnings per share (Unadj.) Rs51.0-26.0-  
Cash flow per share (Unadj.) Rs57.3-21.6-  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.881.1-  
Shares outstanding (eoy) m265.47168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.9 255.5%   
Avg P/E ratio x27.0-11.5 -235.4%  
P/CF ratio (eoy) x24.0-13.9 -173.4%  
Price / Book Value ratio x5.33.7 142.7%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,59250,448 724.7%   
No. of employees `00011.84.3 276.0%   
Total wages/salary Rs m5,4233,166 171.3%   
Avg. sales/employee Rs Th4,175.14,061.4 102.8%   
Avg. wages/employee Rs Th457.7737.5 62.1%   
Avg. net profit/employee Rs Th1,141.8-1,023.4 -111.6%   
INCOME DATA
Net Sales Rs m49,46317,436 283.7%  
Other income Rs m1,556122 1,274.6%   
Total revenues Rs m51,01917,558 290.6%   
Gross profit Rs m18,718-3,021 -619.5%  
Depreciation Rs m1,689753 224.4%   
Interest Rs m35472 7.4%   
Profit before tax Rs m18,551-4,124 -449.8%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023258 1,949.3%   
Profit after tax Rs m13,527-4,393 -307.9%  
Gross profit margin %37.8-17.3 -218.4%  
Effective tax rate %27.1-6.2 -433.4%   
Net profit margin %27.3-25.2 -108.5%  
BALANCE SHEET DATA
Current assets Rs m46,50112,770 364.1%   
Current liabilities Rs m8,4687,185 117.8%   
Net working cap to sales %76.932.0 240.0%  
Current ratio x5.51.8 309.0%  
Inventory Days Days131111 117.9%  
Debtors Days Days86124 69.3%  
Net fixed assets Rs m25,7977,444 346.6%   
Share capital Rs m53181 655.8%   
"Free" reserves Rs m68,9620-   
Net worth Rs m69,49313,685 507.8%   
Long term debt Rs m04,809 0.0%   
Total assets Rs m80,38325,852 310.9%  
Interest coverage x531.0-7.7 -6,867.6%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.7 91.2%   
Return on assets %16.9-15.2 -111.2%  
Return on equity %19.5-32.1 -60.6%  
Return on capital %26.7-19.8 -135.0%  
Exports to sales %00-   
Imports to sales %24.60-   
Net fx Rs m28,8330-   
CASH FLOW
From Operations Rs m9,5431,488 641.2%  
From Investments Rs m-6,854-457 1,499.9%  
From Financial Activity Rs m-2,4594,365 -56.3%  
Net Cashflow Rs m2305,396 4.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.79 Rs / ZAR

Compare DIVIS LABORATORIES With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: WYETH  STERLING BIOTECH  NATCO PHARMA  TTK HEALTHCARE  ALEMBIC  



Today's Market

Sensex Trades Over 300 Points Higher; Dow Futures Up by 232 Points(12:30 pm)

Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 389 points, up 0.9% at 44,539 levels.

Related Views On News

PROCTER & GAMBLE HEALTH at All Time High; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Dec 1, 2020 | Updated on Dec 1, 2020

PROCTER & GAMBLE HEALTH share price has hit an all time high at Rs 7,025 (up 1.5%). The BSE HEALTHCARE Index is up by 1.4%. Among the top gainers in the BSE HEALTHCARE Index today are PROCTER & GAMBLE HEALTH (up 1.5%) and ABBOTT INDIA . The top losers include NARAYANA HRUDAYALAYA (down 0.1%) and GSK PHARMA (down 0.3%).

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Dec 1, 2020 | Updated on Dec 1, 2020

DIVIS LABORATORIES share price has hit an all time high at Rs 3,760 (up 2.3%). The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 2.3%) and ABBOTT INDIA . The top losers include DR. LAL PATHLABS (down 0.1%) and JUBILANT LIFE SCIENCES (down 0.4%).

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks (Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits (Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You (Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Is this Sector the Best Contrarian Bet Right Now? (Profit Hunter)

Nov 23, 2020

The risk reward ratio in this beaten down sector may have finally turned for the better.

The Price of Dying, the Cost of Living (The Honest Truth)

Nov 20, 2020

Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DIVIS LABORATORIES SHARE PRICE


Dec 1, 2020 02:08 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - DISHMAN PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

FEATURED VIDEOS

Adani Green: A Future Multibagger or a Big, Speculative Bubble

Is M&M the ITC of Auto Sector?

Don't Let Brokerages Fool You into Buying HUL & Nestle. The Real Money is in These Stocks Right Now...

What to Expect from Stocks during Covid Second Wave?

More Featured Videos

MARKET STATS